Immune checkpoint therapy (ICT) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has provided remarkable clinical responses over the past decade, but these benefits are restricted to a subset of patients with cancer.1 The gene discussed is CTLA4; the disease is cancer.